China Factory Activity Slips in January as Weak Demand Weighs on Growth Outlook 
Asian Currencies Hold Firm as Dollar Rebounds on Fed Chair Nomination Hopes 
Gold Prices Hit Record High Above $5,500 as Iran Strike Fears Fuel Safe-Haven Demand 
Gold Prices Pull Back After Record Highs as January Rally Remains Strong 
UK Vehicle Production Falls Sharply in 2025 Amid Cyberattack, Tariffs, and Industry Restructuring 
U.S. Eases Venezuela Oil Sanctions to Boost American Investment After Maduro Ouster 
Oil Prices Surge Toward Biggest Monthly Gains in Years Amid Middle East Tensions 
Wall Street Slides as Warsh Fed Nomination, Hot Inflation, and Precious Metals Rout Shake Markets 
Gold and Silver Prices Plunge as Trump Taps Kevin Warsh for Fed Chair 
Asian Stocks Waver as Trump Signals Fed Pick, Shutdown Deal and Tech Earnings Stir Markets 
UK Housing Market Gains Momentum in Early 2026 as Mortgage Rates Fall 
Trump Threatens 50% Tariff on Canadian Aircraft Amid Escalating U.S.-Canada Trade Dispute 
Trump to Announce New Federal Reserve Chair Pick as Powell Replacement Looms 
Wall Street Slips as Tech Stocks Slide on AI Spending Fears and Earnings Concerns 
Copper Prices Hit Record Highs as Metals Rally Gains Momentum on Geopolitical Tensions 
Indonesia Stocks Face Fragile Sentiment After MSCI Warning and Market Rout 
Philippine Economy Slows in Late 2025, Raising Expectations of Further Rate Cuts 
China has approved Eli Lilly’s Kisunla, marking another milestone in global efforts to address Alzheimer’s disease. The treatment, designed to slow memory decline and clear brain plaques, offers early-stage patients a unique dosing approach and new hope for managing the disease.
China Approves Kisunla as a New Alzheimer's Treatment Option
After Eisai and Biogen's Leqembi were approved in January, Eli Lilly said late Tuesday that their treatment for early Alzheimer's has been approved by China's medical authorities, giving patients another alternative, Reuters reports.
According to a statement from Lilly, the medication, which is marketed under the trade name Kisunla, has been approved in four key markets: the US, Japan, and the UK. The latest addition to this list is China.
In the same way as Leqembi removes beta-amyloid from the brain, Lilly's Kisunla does the same.
Kisunla Shows Promising Results in Cognitive Decline
Kisunla shown a 29% reduction in the development of cognitive impairments as compared to a placebo in a large, late-stage experiment. Although most occurrences were moderate, it did induce brain edema in approximately 25% of patients and brain bleeding in approximately 33%.
In the United States, the prescribing label for Kisunla bears the FDA's most severe "boxed" safety warning, which, like Leqembi, warns of the possibility of fatal brain enlargement and hemorrhage.
Gradual Dosing and Finite Treatment Benefit Kisunla Users
However, the business reported that the number of patients having potentially significant brain swelling was reduced when Kisunla was started on a more gradual dose schedule.
Another advantage of Kisunla over Leqembi is its finite dosage, which lets patients discontinue treatment once brain scans reveal no more amyloid plaques.
The medicines authority of the European Union is presently evaluating the treatment. In July, the body decided against using Leqembi because the potential for severe brain swelling was not worth the minimal benefit in preventing cognitive loss, Investing.com shares.
Alzheimer’s Drives Majority of Dementia Cases Globally
The World Health Organization reports that between sixty percent and seventy percent of dementia cases are caused by Alzheimer's disease.
